4-Methylamphetamine
| Clinical data | |
|---|---|
| Trade names | Aptrol (proposed) |
| Other names | 4-MA; 4-MeA; para-Methylamphetamine; PMeA; PAL-313; PAL313; p-TAP; Normephedrine; 4-Me-PIA |
| Routes of administration | Oral, intranasal, injection[1][2] |
| Drug class | Serotonin-norepinephrine-dopamine releasing agent (SNDRA); Serotonin receptor modulator; Stimulant; Anorectic; Psychedelic drug |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 6–12 hours[citation needed] |
| Excretion | Urine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H15N |
| Molar mass | 149.237 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
4-Methylamphetamine (4-MA), also known as para-methylamphetamine (PMeA) and by the former proposed brand name Aptrol, is a stimulant and appetite suppressant drug of the phenethylamine and amphetamine families related to mephedrone.[1][2] It is the amphetamine or β-desketo and N-desmethyl analogue of mephedrone (4-methylmethcathinone; 4-MMC).[2]
Use and effects
[edit]According to Alexander Shulgin in his books PiHKAL (Phenethylamines I Have Known and Loved) and The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, 4-MA is active at a dose of 75 mg orally and produces sympathomimetic effects and appetite loss but little stimulation.[1][2] At a higher dose of 150 mg orally, the drug produces signs of mild toxicity such as salivation, coughing, and vomiting.[1][2] It has been reported to produce psychedelic effects at a dose of 160 mg orally or 80 to 120 mg by intramuscular injection, with a plateau at 2 hours and baseline at 4 hours.[2]
Pharmacology
[edit]Pharmacodynamics
[edit]In vitro, 4-methylamphetamine acts as a potent and well-balanced serotonin, norepinephrine, and dopamine releasing agent (SNDRA) with EC50 values of 53.4 nM, 22.2 nM, and 44.1 nM at the serotonin, norepinephrine, and dopamine transporters, respectively.[3]
However, more recent in vivo studies that involved performing microdialysis on rats showed a different trend. These studies showed that 4-methylamphetamine is much more potent at elevating serotonin (~18 x baseline) relative to dopamine (~5 x baseline). The authors speculated that this is because 5-HT release dampens DA release through some mechanism. For example, it was suggested that a possible cause for this could be activation of 5HT2C receptors since this is known to inhibit DA release. In addition there are alternative explanations such as 5-HT release then going on to encourage GABA release, which has an inhibitory effect on DA neurons.[4]
In addition to its activity as a monoamine releasing agent, 4-MA shows weak affinity for the serotonin 5-HT2 and 5-HT1 receptors (Ki = 3,360 nM and 14,800 nM, respectively).[2][5] Its affinity for the serotonin 5-HT2 receptor was similar to that of 2,5-dimethoxyamphetamine (2,5-DMA) and was 10-fold greater than that of para-methoxyamphetamine (PMA) but was 34-fold lower than that of DOM.[5] In more modern research, it showed affinities of 18,000 nM for the serotonin 5-HT1A receptor, 3,300 nM for the serotonin 5-HT2A receptor, and 6,300 nM for the serotonin 5-HT2C receptor.[6] In addition, it was an partial agonist of the serotonin 5-HT2A and 5-HT2B receptors, with EC50 (Emax) values of 3,300 nM (71%) and 860 nM (54%), respectively.[6]
In animal studies, 4-MA was shown to have the lowest rate of self-administration out of a range of similar drugs tested (the others being 3-methylamphetamine, 4-fluoroamphetamine, and 3-fluoroamphetamine), likely as a result of having the highest potency for releasing serotonin relative to dopamine.[3][7]
4-MA produces the head-twitch response in rodents similarly to para-chloroamphetamine (PCA).[8]
| Compound | NE | DA | 5-HT | Ref |
|---|---|---|---|---|
| Dextroamphetamine | 6.6–10.2 | 5.8–24.8 | 698–1,765 | [9][10][11][12] |
| Dextromethamphetamine | 12.3–14.3 | 8.5–40.4 | 736–1,292 | [9][13][11][12] |
| 4-Methylamphetamine | 22.2 | 44.1 | 53.4 | [3][14][11] |
| 4-Methylmethamphetamine (mephedrine) | 66.9 | 41.3 | 67.4 | [15][16] |
| 4-Methylcathinone (normephedrone) | 100 | 220 | 210 | [17][18][19] |
| 4-Methylmethcathinone (mephedrone) | 58–62.7 | 49.1–51 | 118.3–122 | [13][10][20][21][22] |
| Notes: The smaller the value, the more strongly the drug releases the neurotransmitter. The assays were done in rat brain synaptosomes and human potencies may be different. See also Monoamine releasing agent § Activity profiles for a larger table with more compounds. Refs: [23][24] | ||||
Chemistry
[edit]Synthesis
[edit]The chemical synthesis of 4-MA has been described.[2]
Analogues
[edit]Analogues of 4-MA include amphetamine (A), 4-methyl-N-methylamphetamine (4-MMA), mephedrone (4-methyl-N-methylcathinone), 4-ethylamphetamine (4-EA), 4-propylamphetamine (4-PA), 2-methylamphetamine (2-MA), 3-methylamphetamine (3-MA), xylopropamine (3,4-dimethylamphetamine; 3-4-DMeA), 3-methoxy-4-methylamphetamine (MMA; 3,4-MMA), 4-methylphenylisobutylamine (4-MAB), 4-methylphenmetrazine, and 5-APDI, among others.[1][2]
Natural occurrence
[edit]4-Methylamphetamine has been reported to occur naturally as an alkaloid in Thymus quinquecostatus plants, although its content even in young leaves is quite low (3.11 ± 0.05% of the total alkaloid fraction. As the leaves mature, the substance ceases to be detectable.)[25] However, despite the identification of the compound, it is difficult to say whether this study is accurate, given the low level of verifiability and the lack of reliable sources to support the claim.
History
[edit]The psychedelic effects of 4-MA in humans were disclosed by Alexander Shulgin in his book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds.[2] They were provided to Shulgin via personal communication with an individual named Igor.[2]
Society and culture
[edit]Deaths
[edit]More than a dozen deaths were reported throughout Europe in 2012 to 2013 after consumption of amphetamine ('speed') contaminated with 4-MA.[26][27]
Legal status
[edit]United States
[edit]4-MA is not an explicitly controlled substance in the United States.[2] However, it could be considered a Schedule I controlled substance under the Federal Analogue Act.
Research
[edit]4-MA was investigated as an appetite suppressant in 1952 and was even given a trade name, Aptrol, but development was apparently never completed.[28] More recently it has been reported as a novel designer drug.
See also
[edit]References
[edit]- 1 2 3 4 5 Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. "All three isomers of monomethylamphetamine have also been looked at in man. The ortho- and meta-isomers, 2-methyl- (and 3-methyl-) amphetamine are weak anorexics. At doses of up to 150 milligrams orally, there were signs of stimulation noted—talkativeness and loss of appetite. The para-isomer, 4-methylamphetamine or Aptrol, is more potent. At 75 milligrams (orally, in man) there is clear adrenergic stimulation, and at twice this dosage there are signs of mild toxicity such as salivation, coughing and vomiting."
- 1 2 3 4 5 6 7 8 9 10 11 12 Shulgin A, Manning T, Daley PF (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley: Transform Press. ISBN 978-0-9630096-3-0.
- 1 2 3 Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL (May 2005). "Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs". The Journal of Pharmacology and Experimental Therapeutics. 313 (2): 848–854. doi:10.1124/jpet.104.080101. PMID 15677348. S2CID 12135483.
- ↑ Di Giovanni G, Esposito E, Di Matteo V (June 2010). "Role of serotonin in central dopamine dysfunction". CNS Neuroscience & Therapeutics. 16 (3): 179–194. doi:10.1111/j.1755-5949.2010.00135.x. PMC 6493878. PMID 20557570.
- 1 2 Shannon M, Battaglia G, Glennon RA, Titeler M (June 1984). "5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA)". European Journal of Pharmacology. 102 (1): 23–29. doi:10.1016/0014-2999(84)90333-9. PMID 6479216.
- 1 2 Luethi D, Kolaczynska KE, Docci L, Krähenbühl S, Hoener MC, Liechti ME (May 2018). "Pharmacological profile of mephedrone analogs and related new psychoactive substances". Neuropharmacology. 134 (Pt A): 4–12. doi:10.1016/j.neuropharm.2017.07.026. PMID 28755886.
- ↑ Baumann MH, Clark RD, Woolverton WL, Wee S, Blough BE, Rothman RB (April 2011). "In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat". The Journal of Pharmacology and Experimental Therapeutics. 337 (1): 218–225. doi:10.1124/jpet.110.176271. PMC 3063744. PMID 21228061.
- ↑ Ogren SO, Ross SB (October 1977). "Substituted amphetamine derivatives. II. Behavioural effects in mice related to monoaminergic neurones". Acta Pharmacologica et Toxicologica. 41 (4). Copenh: 353–368. doi:10.1111/j.1600-0773.1977.tb02674.x. PMID 303437.
- 1 2 Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, et al. (January 2001). "Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin". Synapse. 39 (1). New York, N.Y.: 32–41. doi:10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3. PMID 11071707. S2CID 15573624.
- 1 2 Baumann MH, Partilla JS, Lehner KR, Thorndike EB, Hoffman AF, Holy M, et al. (March 2013). "Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products". Neuropsychopharmacology. 38 (4): 552–562. doi:10.1038/npp.2012.204. PMC 3572453. PMID 23072836.
- 1 2 3 Blough B (July 2008). "Dopamine-releasing agents" (PDF). In Trudell ML, Izenwasser S (eds.). Dopamine Transporters: Chemistry, Biology and Pharmacology. Hoboken [NJ]: Wiley. pp. 305–320. ISBN 978-0-470-11790-3. OCLC 181862653. OL 18589888W.
- 1 2 Partilla JS, Dersch CM, Baumann MH, Carroll FI, Rothman RB (1999). "Profiling CNS Stimulants with a High-Throughput Assay for Biogenic Amine Transporter Substrates". Problems of Drug Dependence 1999: Proceedings of the 61st Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc (PDF). NIDA Res Monogr. Vol. 180. pp. 1–476 (252). PMID 11680410. Archived from the original (PDF) on 28 November 2024.
RESULTS. Methamphetamine and amphetamine potently released NE (IC50s = 14.3 and 7.0 nM) and DA (IC50s = 40.4 nM and 24.8 nM), and were much less potent releasers of 5-HT (IC50s = 740 nM and 1765 nM). Phentermine released all three biogenic amines with an order of potency NE (IC50 = 28.8 nM)> DA (IC50 = 262 nM)> 5-HT (IC50 = 2575 nM). Aminorex released NE (IC50 = 26.4 nM), DA (IC50 = 44.8 nM) and 5-HT (IC50 = 193 nM). Chlorphentermine was a very potent 5-HT releaser (IC50 = 18.2 nM), a weaker DA releaser (IC50 = 935 nM) and inactive in the NE release assay. Chlorphentermine was a moderate potency inhibitor of [3H]NE uptake (Ki = 451 nM). Diethylpropion, which is self-administered, was a weak DA uptake inhibitor (Ki = 15 µM) and NE uptake inhibitor (Ki = 18.1 µM) and essentially inactive in the other assays. Phendimetrazine, which is self-administered, was a weak DA uptake inhibitor (IC50 = 19 µM), a weak NE uptake inhibitor (8.3 µM) and essentially inactive in the other assays.
- 1 2 Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. (April 2012). "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology. 37 (5): 1192–1203. doi:10.1038/npp.2011.304. PMC 3306880. PMID 22169943.
- ↑ Forsyth AN (22 May 2012). "Synthesis and Biological Evaluation of Rigid Analogues of Methamphetamines". ScholarWorks@UNO. Retrieved 4 November 2024.
- ↑ Solis E, Partilla JS, Sakloth F, Ruchala I, Schwienteck KL, De Felice LJ, et al. (September 2017). "N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability". Neuropsychopharmacology. 42 (10): 1950–1961. doi:10.1038/npp.2017.98. PMC 5561352. PMID 28530234.
- ↑ Sakloth F (11 December 2015). Psychoactive synthetic cathinones (or 'bath salts'): Investigation of mechanisms of action. VCU Scholars Compass (Thesis). doi:10.25772/AY8R-PW77.
- ↑ Mayer FP, Wimmer L, Dillon-Carter O, Partilla JS, Burchardt NV, Mihovilovic MD, et al. (September 2016). "Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters". British Journal of Pharmacology. 173 (17): 2657–2668. doi:10.1111/bph.13547. PMC 4978154. PMID 27391165.
- ↑ Hutsell BA, Baumann MH, Partilla JS, Banks ML, Vekariya R, Glennon RA, et al. (February 2016). "Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats". European Neuropsychopharmacology. 26 (2): 288–297. doi:10.1016/j.euroneuro.2015.12.010. PMC 5331761. PMID 26738428.
- ↑ Glennon RA, Dukat M (2017). "Structure-Activity Relationships of Synthetic Cathinones". Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences. Vol. 32. pp. 19–47. doi:10.1007/7854_2016_41. ISBN 978-3-319-52442-9. PMC 5818155. PMID 27830576.
- ↑ Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, et al. (March 2019). "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology. 236 (3). Berl: 915–924. doi:10.1007/s00213-018-5063-9. PMC 6475490. PMID 30341459.
- ↑ Walther D, Shalabi AR, Baumann MH, Glennon RA (January 2019). "Systematic Structure-Activity Studies on Selected 2-, 3-, and 4-Monosubstituted Synthetic Methcathinone Analogs as Monoamine Transporter Releasing Agents". ACS Chemical Neuroscience. 10 (1): 740–745. doi:10.1021/acschemneuro.8b00524. PMC 8269283. PMID 30354055.
- ↑ Bonano JS, Banks ML, Kolanos R, Sakloth F, Barnier ML, Glennon RA, et al. (May 2015). "Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues". British Journal of Pharmacology. 172 (10): 2433–2444. doi:10.1111/bph.13030. PMC 4409897. PMID 25438806.
- ↑ Rothman RB, Baumann MH (October 2003). "Monoamine transporters and psychostimulant drugs". European Journal of Pharmacology. 479 (1–3): 23–40. doi:10.1016/j.ejphar.2003.08.054. PMID 14612135.
- ↑ Rothman RB, Baumann MH (2006). "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry. 6 (17): 1845–1859. doi:10.2174/156802606778249766. PMID 17017961.
- ↑ Jing H, Liu J, Liu H, Xin H (2014). "Histochemical investigation and kinds of alkaloids in leaves of different developmental stages in Thymus quinquecostatus". TheScientificWorldJournal. 2014 839548. doi:10.1155/2014/839548. PMC 4102088. PMID 25101324.
- ↑ Blanckaert P, van Amsterdam J, Brunt T, van den Berg J, Van Durme F, Maudens K, et al. (September 2013). "4-Methyl-amphetamine: a health threat for recreational amphetamine users". Journal of Psychopharmacology. 27 (9). Oxford, England: 817–822. doi:10.1177/0269881113487950. PMID 23784740. S2CID 35436194.
- ↑ Coppola M, Mondola R (December 2013). "4-methylamphetamine (4-MA): chemistry, pharmacology and toxicology of a new potential recreational drug". Mini Reviews in Medicinal Chemistry. 13 (14): 2097–2101. doi:10.2174/13895575113136660106. PMID 24195663.
- ↑ Gelvin EP, McGavack TH (January 1952). "2-Amino-1-(p-methylphenyl)-propane (aptrol) as an anorexigenic agent in weight reduction". New York State Journal of Medicine. 52 (2): 223–226. PMID 14890975.